The results are very encouraging news for Amgen and Repatha, which is in a head-to-head marketing battle with Sanofi and Regeneron’s Praluent to be the dominant PCSK9 inhibitor.

Learn about side effects, cost, dosage, and more for Repatha (evolocumab). It’s a prescription drug used to treat high cholesterol or heart disease.

How Was Repatha Studied for Lowering LDL Cholesterol? Clinical studies were done to test if Repatha was safe and effective for lowering cholesterol in people with heart disease or high cholesterol.

It’s not known whether Repatha (evolocumab) is safe to use while pregnant or breastfeeding. Certain factors may determine whether you should use the drug during this time.

Rosie O’Donnell shared how she feels about her recent dramatic weight loss in a May 23 Instagram post alongside a photo of her slimmer body.

Leqvio (inclisiran) and Repatha (evelocumab) are prescription injectable medications used to treat high cholesterol. They specifically target low-density lipoprotein cholesterol (LDL-C), or "bad ...

Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US, raising the chance that American payers will seek hefty discounts on the drug ...

In 2016, Amgen (AMGN) expects Repatha, a novel PCSK9 inhibitor drug, to continue to capture global market share in the atherosclerosis segment.

Amgen said it will sell the cholesterol drug Repatha only at a list price 60% lower than its original price in a bid to make the medicine more affordable for patients and kick-start sales.

Repatha, designed to work with a similar mechanism to reduce low-density lipoprotein (LDL) cholesterol, or “bad” cholesterol, added $2.2B in sales for Amgen (AMGN) in the same year with ~36% ...

Amgen's Repatha is the second drug in a new class of cholesterol lowering drugs, called PCSK9 inhibitors, to win FDA approval.

Amgen Inc's battle with Sanofi and Regeneron at the U.S. Supreme Court over its cholesterol drug Repatha on Monday has some drugmakers hoping a ruling will reshape U.S. patent law and competition ...